Evolution of aortic valve replacement in children

A single center experience

Mark Ruzmetov, Palaniswamy Vijay, Mark Rodefeld, Mark Turrentine, John Brown

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: The availability of an ideal prosthesis for aortic valve replacement (AVR) in children remains controversial due to an early degeneration of xenografts and the potential risks related to anticoagulation with mechanical prostheses. This has led many surgeons to the Ross procedure. This study outlines the evolution of our 30-year experience with AVR in children. Methods: One hundred and forty-seven children, aged 10 days to 18 years (mean 11.9 ± 5.7 years), underwent AVR between 1974 and June 2005. Preoperative diagnosis included aortic insufficiency (n = 39), aortic stenosis (n = 14), combined aortic stenosis with insufficiency (n = 78), and complex left ventricular outflow tract obstruction (n = 16). Xenografts (n = 11) and mechanical prostheses (n = 47) were used in 58 patients. The remaining 89 patients had placement of homografts (n = 8) or underwent a Ross procedure (n = 81). Of the 147 patients, 87 (59%) had previous procedures. Results: Overall early and late mortality was 7.5% (11 / 147 pts). Overall survival estimated by the Kaplan-Meier method, including early mortality, was 94% at 1 year, and 93% at 5, 10, and 20 years. Univariate and multivariate analysis identified date of operation (before 1980) as a risk factor for death (p = 0.002). Follow-up was complete in 136 patients (5 lost to follow-up), with a total follow-up of 2433.72 patient-years. The overall study group aortic valve-related reoperation rate was 20% (20 / 138 pts), the reoperation rate was highest in xenograft group (60%); followed by mechanical valves group (16%), homograft group (14%), and the Ross procedure group (9%). Ross patients showed significant increase of the annulus diameter (p = 0.002) and the aortic sinus diameter (p = 0.01) at the last follow-up. The actuarial rate for freedom from aortic valve-related reoperation was 99% at 1 year, 94% at 5 years, 88% at 10 years, and 85% at 20 years. Univariate and multivariate analysis identified the presence of a xenograft as a risk factor for aortic valve-related reoperation (p = 0.001). Conclusion: AVR in children can be performed with acceptable mortality and minimal mid-term morbidity. The Ross procedure, although more complicated, has the advantage of not requiring anticoagulation. Pulmonary autograft, in our series, has demonstrated growth with no structural degeneration. The potential for development of significant autograft insufficiency and ascending aortic aneurysmal dilatation is small but warrants annual follow-up. Our data supports that the Ross procedure is the AVR of choice in children.

Original languageEnglish
Pages (from-to)194-200
Number of pages7
JournalInternational Journal of Cardiology
Volume113
Issue number2
DOIs
StatePublished - Nov 10 2006

Fingerprint

Aortic Valve
Reoperation
Heterografts
Prostheses and Implants
Aortic Valve Stenosis
Autografts
Allografts
Mortality
Multivariate Analysis
Ventricular Outflow Obstruction
Sinus of Valsalva
Lost to Follow-Up
Dilatation
Morbidity
Lung
Survival
Growth

Keywords

  • Aortic valve replacement
  • Homograft
  • Ross procedure
  • Xenograft

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Evolution of aortic valve replacement in children : A single center experience. / Ruzmetov, Mark; Vijay, Palaniswamy; Rodefeld, Mark; Turrentine, Mark; Brown, John.

In: International Journal of Cardiology, Vol. 113, No. 2, 10.11.2006, p. 194-200.

Research output: Contribution to journalArticle

@article{7ea39f59ad9c46c5be4776ea1f90f7b3,
title = "Evolution of aortic valve replacement in children: A single center experience",
abstract = "Background: The availability of an ideal prosthesis for aortic valve replacement (AVR) in children remains controversial due to an early degeneration of xenografts and the potential risks related to anticoagulation with mechanical prostheses. This has led many surgeons to the Ross procedure. This study outlines the evolution of our 30-year experience with AVR in children. Methods: One hundred and forty-seven children, aged 10 days to 18 years (mean 11.9 ± 5.7 years), underwent AVR between 1974 and June 2005. Preoperative diagnosis included aortic insufficiency (n = 39), aortic stenosis (n = 14), combined aortic stenosis with insufficiency (n = 78), and complex left ventricular outflow tract obstruction (n = 16). Xenografts (n = 11) and mechanical prostheses (n = 47) were used in 58 patients. The remaining 89 patients had placement of homografts (n = 8) or underwent a Ross procedure (n = 81). Of the 147 patients, 87 (59{\%}) had previous procedures. Results: Overall early and late mortality was 7.5{\%} (11 / 147 pts). Overall survival estimated by the Kaplan-Meier method, including early mortality, was 94{\%} at 1 year, and 93{\%} at 5, 10, and 20 years. Univariate and multivariate analysis identified date of operation (before 1980) as a risk factor for death (p = 0.002). Follow-up was complete in 136 patients (5 lost to follow-up), with a total follow-up of 2433.72 patient-years. The overall study group aortic valve-related reoperation rate was 20{\%} (20 / 138 pts), the reoperation rate was highest in xenograft group (60{\%}); followed by mechanical valves group (16{\%}), homograft group (14{\%}), and the Ross procedure group (9{\%}). Ross patients showed significant increase of the annulus diameter (p = 0.002) and the aortic sinus diameter (p = 0.01) at the last follow-up. The actuarial rate for freedom from aortic valve-related reoperation was 99{\%} at 1 year, 94{\%} at 5 years, 88{\%} at 10 years, and 85{\%} at 20 years. Univariate and multivariate analysis identified the presence of a xenograft as a risk factor for aortic valve-related reoperation (p = 0.001). Conclusion: AVR in children can be performed with acceptable mortality and minimal mid-term morbidity. The Ross procedure, although more complicated, has the advantage of not requiring anticoagulation. Pulmonary autograft, in our series, has demonstrated growth with no structural degeneration. The potential for development of significant autograft insufficiency and ascending aortic aneurysmal dilatation is small but warrants annual follow-up. Our data supports that the Ross procedure is the AVR of choice in children.",
keywords = "Aortic valve replacement, Homograft, Ross procedure, Xenograft",
author = "Mark Ruzmetov and Palaniswamy Vijay and Mark Rodefeld and Mark Turrentine and John Brown",
year = "2006",
month = "11",
day = "10",
doi = "10.1016/j.ijcard.2005.11.011",
language = "English",
volume = "113",
pages = "194--200",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Evolution of aortic valve replacement in children

T2 - A single center experience

AU - Ruzmetov, Mark

AU - Vijay, Palaniswamy

AU - Rodefeld, Mark

AU - Turrentine, Mark

AU - Brown, John

PY - 2006/11/10

Y1 - 2006/11/10

N2 - Background: The availability of an ideal prosthesis for aortic valve replacement (AVR) in children remains controversial due to an early degeneration of xenografts and the potential risks related to anticoagulation with mechanical prostheses. This has led many surgeons to the Ross procedure. This study outlines the evolution of our 30-year experience with AVR in children. Methods: One hundred and forty-seven children, aged 10 days to 18 years (mean 11.9 ± 5.7 years), underwent AVR between 1974 and June 2005. Preoperative diagnosis included aortic insufficiency (n = 39), aortic stenosis (n = 14), combined aortic stenosis with insufficiency (n = 78), and complex left ventricular outflow tract obstruction (n = 16). Xenografts (n = 11) and mechanical prostheses (n = 47) were used in 58 patients. The remaining 89 patients had placement of homografts (n = 8) or underwent a Ross procedure (n = 81). Of the 147 patients, 87 (59%) had previous procedures. Results: Overall early and late mortality was 7.5% (11 / 147 pts). Overall survival estimated by the Kaplan-Meier method, including early mortality, was 94% at 1 year, and 93% at 5, 10, and 20 years. Univariate and multivariate analysis identified date of operation (before 1980) as a risk factor for death (p = 0.002). Follow-up was complete in 136 patients (5 lost to follow-up), with a total follow-up of 2433.72 patient-years. The overall study group aortic valve-related reoperation rate was 20% (20 / 138 pts), the reoperation rate was highest in xenograft group (60%); followed by mechanical valves group (16%), homograft group (14%), and the Ross procedure group (9%). Ross patients showed significant increase of the annulus diameter (p = 0.002) and the aortic sinus diameter (p = 0.01) at the last follow-up. The actuarial rate for freedom from aortic valve-related reoperation was 99% at 1 year, 94% at 5 years, 88% at 10 years, and 85% at 20 years. Univariate and multivariate analysis identified the presence of a xenograft as a risk factor for aortic valve-related reoperation (p = 0.001). Conclusion: AVR in children can be performed with acceptable mortality and minimal mid-term morbidity. The Ross procedure, although more complicated, has the advantage of not requiring anticoagulation. Pulmonary autograft, in our series, has demonstrated growth with no structural degeneration. The potential for development of significant autograft insufficiency and ascending aortic aneurysmal dilatation is small but warrants annual follow-up. Our data supports that the Ross procedure is the AVR of choice in children.

AB - Background: The availability of an ideal prosthesis for aortic valve replacement (AVR) in children remains controversial due to an early degeneration of xenografts and the potential risks related to anticoagulation with mechanical prostheses. This has led many surgeons to the Ross procedure. This study outlines the evolution of our 30-year experience with AVR in children. Methods: One hundred and forty-seven children, aged 10 days to 18 years (mean 11.9 ± 5.7 years), underwent AVR between 1974 and June 2005. Preoperative diagnosis included aortic insufficiency (n = 39), aortic stenosis (n = 14), combined aortic stenosis with insufficiency (n = 78), and complex left ventricular outflow tract obstruction (n = 16). Xenografts (n = 11) and mechanical prostheses (n = 47) were used in 58 patients. The remaining 89 patients had placement of homografts (n = 8) or underwent a Ross procedure (n = 81). Of the 147 patients, 87 (59%) had previous procedures. Results: Overall early and late mortality was 7.5% (11 / 147 pts). Overall survival estimated by the Kaplan-Meier method, including early mortality, was 94% at 1 year, and 93% at 5, 10, and 20 years. Univariate and multivariate analysis identified date of operation (before 1980) as a risk factor for death (p = 0.002). Follow-up was complete in 136 patients (5 lost to follow-up), with a total follow-up of 2433.72 patient-years. The overall study group aortic valve-related reoperation rate was 20% (20 / 138 pts), the reoperation rate was highest in xenograft group (60%); followed by mechanical valves group (16%), homograft group (14%), and the Ross procedure group (9%). Ross patients showed significant increase of the annulus diameter (p = 0.002) and the aortic sinus diameter (p = 0.01) at the last follow-up. The actuarial rate for freedom from aortic valve-related reoperation was 99% at 1 year, 94% at 5 years, 88% at 10 years, and 85% at 20 years. Univariate and multivariate analysis identified the presence of a xenograft as a risk factor for aortic valve-related reoperation (p = 0.001). Conclusion: AVR in children can be performed with acceptable mortality and minimal mid-term morbidity. The Ross procedure, although more complicated, has the advantage of not requiring anticoagulation. Pulmonary autograft, in our series, has demonstrated growth with no structural degeneration. The potential for development of significant autograft insufficiency and ascending aortic aneurysmal dilatation is small but warrants annual follow-up. Our data supports that the Ross procedure is the AVR of choice in children.

KW - Aortic valve replacement

KW - Homograft

KW - Ross procedure

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=33750478014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750478014&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2005.11.011

DO - 10.1016/j.ijcard.2005.11.011

M3 - Article

VL - 113

SP - 194

EP - 200

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -